Gastrointestinal stromal tumors

Cancer Control

Volumn 8, Issue 3, 2001, Pages 252-261

  Strickland, Leah ^a   Letson, G Douglas ^a   Muro Cacho, Carlos A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; INTERLEUKIN 3; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TUMOR MARKER; TYROSINE KINASE RECEPTOR;

ARTICLE; COLON TUMOR; ESOPHAGUS TUMOR; EXON; GASTROINTESTINAL TUMOR; GENE MUTATION; INTESTINE CELL; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMOMA; METASTASIS; PREVALENCE; PROTO ONCOGENE; RECTUM TUMOR; SMALL INTESTINE TUMOR; STOMACH TUMOR; STROMA;

EID: 0035002106     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480100800305     Document Type: Article

References (72)

1. Bizarre smooth muscle tumors of the stomach
2. Gastrointestinal stromal tumors: Recent advances in understanding of their biology
3. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas: Implications for surgical management and staging
4. Gastrointestinal stromal tumors
5. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal)
6. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours
7. Mesenchymal tumors of the gastrointestinal tract: A paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases?
8. Mutation of the protooncogene c-kit blocks development of interstitial cells and electrical rhythmicity, in murine intestine
9. Ultrastructural study of relationships between c-kit immunoreactive interstitial cells and other cellular elements in the human colon
10. c-Kit immunoreactive interstitial cells in the human gastrointestinal tract
11. c-kit immunoreactive interstitial cells of Cajal in the human small and large intestine
12. Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells
13. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase
14. Transformation of thyroid epithelium is associated with loss of c-kit receptor
15. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas
16. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
17. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
18. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors
19. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene
20. Familial gastrointestinal stromal tumours with germline mutations of the KIT gene
21. Effects of loss-of-function and gain-of-function mutations of c-kit on the gastrointestinal tract
22. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors
23. Gastrointestinal stromal tumors: Value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas
24. Gastrointestinal pacemaker cell tumor: Clinicopathological, immunohistochemical, and ultrastructural study with special reference to c-kit receptor antibody
25. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal
26. CD34+ cells in human intestine are fibroblasts adjacent to, but distinct from, interstitial cells of Cajal
27. CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34
28. Gastrointestinal stromal tumors: Definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis
29. Muscle differentiation and clinicopathologic features of gastrointestinal stromal tumors
30. Stromal tumors of the gastrointestinal tract: Myogenic or neurogenic?
31. Gastrointestinal stromal tumours: An immunohistochemical study of 165 cases
32. The immunohistochemistry of gastrointestinal stromal tumors: Evidence supporting an origin from smooth muscle
33. Esophageal stromal tumors: A clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas
34. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases
35. Gastrointestinal stromal tumors: Recent advances in understanding of their biology
36. Gastrointestinal stromal tumors: An immunohistochemical study of cellular differentiation
37. Gastrointestinal stromal tumor: Evidence for a smooth-muscle origin
38. Gastrointestinal stromal tumor (GIST): Morphologic and immunohistochemical study of 10 cases
39. Gastrointestinal autonomic nerve tumors: "Plexosarcomas"
40. Gastrointestinal autonomic tumor associated with von Recklinghausen's disease
41. Gastrointestinal autonomic nerve tumors: Immunohistochemical and ultrastructural studies in cases of gastrointestinal stromal tumor
42. Gastrointestinal autonomic nerve tumors: A clinicopathological, immunohistochemical, and ultrastructural study of 12 cases
43. Gastrointestinal autonomic nerve tumor: Further observations regarding an ultrastructural and immunohistochemical analysis of six cases
44. Subclassification of gastrointestinal stromal tumors based on evaluation by electron microscopy and immunohistochemistry
45. Gastrointestinal autonomic nerve tumor: A case report with electron microscopic and immunohistochemical analysis and review of the literature
46. Gastrointestinal autonomic nerve (GAN) tumor: Ultrastructural evidence for a newly recognized entity
47. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT)
48. Inflammatory cell-rich gastrointestinal autonomic nerve tumor: An expansion of its histologic spectrum
49. Gastrointestinal stromal tumors with prominent myxoid matrix: Clinicopathologic, immunohistochemical, and ultrastructural study of nine cases of a distinctive morphologic variant of myogenic stromal tumor
50. Gastric leiomyosarcoma: Prognostic factors and surgical management
51. Gastrointestinal stromal tumours: Correlation of immunophenotype with clinicopathological features
52. Smooth muscle tumors of the gastrointestinal tract: A study of 56 cases followed for a minimum of 10 years
53. Sarcomas of the gastrointestinal tract: Separation into favorable and unfavorable prognostic groups by mitotic count
54. Smooth muscle tumors of the gastrointestinal tract: Analysis of prognostic factors
55. Prognostic factors in primary gastrointestinal leiomyosarcoma: A retrospective study
56. Primary gastrointestinal sarcomas: Analysis of prognostic variables
57. Gastrointestinal sarcomas: Analysis of prognostic factors
58. Gut stromal tumors and their clinical behavior
59. DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression and prognostic significance
60. Highresolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci
61. Gastrointestinal stromal tumor, uncommitted type, with monosomies 14 and 22 as the only chromosomal abnormalities
62. A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (AgNOR) staining, and histological grading in gastrointestinal stromal tumours
63. Prognostic factors of gastrointestinal stromal tumors of the stomach
64. Coincidence of Crohn's disease and a high-risk gastrointestinal stromal tumor of the terminal ileum
65. Endosonographic differentiation of benign and malignant stromal cell tumors
66. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival
67. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
68. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
69. Brief report: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
70. Evaluation of the safety and efficacy of an oral molecularly targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors expressing c-kit (CD117)
71. STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST): An EORTC phase I study